Recent Updates — OSRHW
The Nasdaq Hearings Panel has denied OSR Health, Inc.'s request for continued listing and determined to delist the company's common stock and warrants from The Nasdaq Stock Market due to non-compliance with the $1.00 minimum bid price requirement. Trading was previously suspended on August 26, 2026, and securities now trade on the over-the-counter market under symbols OSRH and OSRHW. The company stated it chose not to pursue a reverse stock split during the compliance process and is evaluating strategic options to regain listing status, with an update expected by November 6, 2026. OSR Health operates as a global healthcare holding company advancing biomedical innovations in immuno-oncology, regenerative biologics, and medical device technologies.
OSR Health, Inc. entered into Amendment No. 1 to its Global Exclusive License Agreement with BCM Europe AG, creating a Convertible Note Option to settle the existing Equity Option. This change follows Nasdaq's delisting determination for OSRH common stock on August 19, 2026. The amendment allows OSR Health to issue up to $15 million in aggregate principal amount of convertible notes, issued in four tranches of $3.75 million each. These notes are convertible into common stock at fixed prices of approximately $2.00, $3.00, $4.00, and $5.00 per share, subject to Nasdaq's Minimum Price rule. BCM Europe AG must deliver a binding commitment from a purchaser with the election notice, with closing occurring no fewer than twenty business days after notice. If closing fails within ten business days of the scheduled date, the option reverts to equity settlement. OSR Health operates in the biopharmaceutical industry, focusing on vaccine development and immunotherapy.
On September 30, 2026, Dr. Constance Hoefer resigned as Chief Scientific Officer of OSR Health, Inc., with immediate effect and no underlying dispute. The company operates in the biotechnology industry.
OSR Health, Inc. announced that Nasdaq confirmed its Shareholder Loyalty Contingent Value Rights (CVR) program will not trigger a mechanical price adjustment to the common stock upon distribution or delivery of additional shares. The record date for eligibility is August 14, 2026. This clarification ensures enrolled shareholders receive additional shares at no cost as price milestones are met, with value determined by market forces rather than exchange adjustments. OSR Health operates in the healthcare industry, specifically advancing biomedical innovations through immuno-oncology, regenerative biologics, and medical device technologies.